Drug intelligence / Profile preview

human islet amyloid polypeptide

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Intraplantar, Intravenous

Overview

Human islet amyloid polypeptide (hIAPP) is a protein that forms pathogenic aggregates. These aggregates are known to damage pancreatic islet β cells in type 2 diabetes mellitus (T2DM) and are implicated in T2DM-associated peripheral neuropathy. Aggregated hIAPP is neurotoxic, reducing neurite outgrowth and increasing mitochondrial reactive oxygen species in sensory neurons. Its aggregation is a key factor in mediating peripheral neuropathy, and pharmacological inhibition of hIAPP aggregation has been shown to prevent these neuropathic effects.

Other names: hIAPP

Targets

IAPP (Islet Amyloid Polypeptide)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on human islet amyloid polypeptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human islet amyloid polypeptide.

Explore the full profile